Proximal protection devices could be the first choice for most carotid artery stenting procedures

Original title: Evaluation of proximal protection devices during carotid artery stenting as the first choice for embolic protection. Reference: Hornung M et al. EuroIntervention. 2014; Epub ahead of print.

This series of the Frankfurt CardioVascular Center included 124 consecutive patients undergoing carotid angioplasty with proximal protection. The first 92 patients received the Gore Flow Reversal System (WL Gore; Flagstaff, AZ). After this device became unavailable the Mo.Ma Ultra was used (Medtronic; Minneapolis, MN).

After procedure, all patients were prescribed 100 mg of aspirin indefinitely, and 75 mg of clopidogrel daily for at least 30 days. 21% of the population presented a symptomatic lesion; mean time between index neurological event and stenting was 50.5 days.

Predilation was necessary in 33.1% of lesions and most commonly employed stents were the Protege (Ev3 Endovascular; Plymouth, MN; 56.5%) and the Xact (Abbott Vascular; Santa Clara, CA; 24.2%).

The primary end point, a combination of new transitory ischemic accident and minor or major stroke within 30 days, was observed in one patient only. This patient had no procedural complications but suffered a stent thrombosis 9 days after discharge.

Transitory neurological symptoms due to intolerance of antegrade flow interruption during balloon occlusion were observed in 10 patients (8.1%), but were promptly and completely solved once flow was reestablished.

Only 2 patients were not able to benefit from the proximal embolic protection device, which had a technical success of 98.4%. None of these patients presented neurological complications.

Conclusion

Proximal protection devices are safe and can be used as first choice for embolic protection during carotid artery stenting. 

Editorial Comment

Neurological complications rate with proximal protection (both in the meta-analysis and the current series) is lower than rates reported by the majority of studies comparing carotid stenting with distal protection vs endarterectomy. Outcomes of this study, from one center only, with very few expert operators, may not be transferable to other centers. 

SOLACI.ORG

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...